Form 4: Oruka Therapeutics CEO Sells Shares
Insider Transaction (Form 4)
Lawrence Otto Klein, Chief Executive Officer and a Director of Oruka Therapeutics, Inc., sold 25,000 shares of common stock on October 1, 2026.
Summary
- Option exercise/conversion: acquired 25,000 Common Stock at $7.80 ($195,000) on October 1, 2026; holds 948,128 after (Direct).
- Open-market sale: disposed of 16,246 Common Stock at $83.40 ($1,354,882) on October 1, 2026; holds 931,882 after (Direct).
- Open-market sale: disposed of 8,554 Common Stock at $84.03 ($718,755) on October 1, 2026; holds 923,328 after (Direct).
- Open-market sale: disposed of 200 Common Stock at $84.78 ($16,956) on October 1, 2026; holds 923,128 after (Direct).
- Option exercise/conversion: disposed of 25,000 Employee Warrant (right to buy) on October 1, 2026; holds 1,528,513 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $2,090,593 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Lawrence Otto Klein — Director, Officer (Chief Executive Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-01 | Option exercise/conversion | Common Stock | 25,000 | $8 | $195.0K | 948,128 |
| 2026-10-01 | Open-market sale | Common Stock | 16,246 | $83 | $1.4M | 931,882 |
| 2026-10-01 | Open-market sale | Common Stock | 8,554 | $84 | $718.8K | 923,328 |
| 2026-10-01 | Open-market sale | Common Stock | 200 | $85 | $17.0K | 923,128 |
| 2026-10-01 | Option exercise/conversion | Employee Warrant (right to buy) | 25,000 | — | — | 1,528,513 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-01 | Option exercise/conversion (25,000 shares) |
| 2026-10-01 | Open-market sale (16,246 shares) |
| 2026-10-01 | Open-market sale (8,554 shares) |
| 2026-10-01 | Open-market sale (200 shares) |
| 2026-10-01 | Option exercise/conversion (25,000 shares) |
Keywords
insider transaction, Form 4, ORKA, Oruka Therapeutics, Inc., bearish, Lawrence Otto Klein
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.